Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Administering stem cells to patients with myocardial infarction leads to a reduction of the size of the infarct

10.01.2006


This week, doctors at the Catholic University of Leuven, connected with the University Hospital - Gasthuisberg, the Stem Cell Institute Leuven (SCIL), and the Flanders Interuniversity Institute for Biotechnology (VIB), are publishing a major breakthrough in the treatment of patients with acute myocardial infarction. Their research shows that the administration of a patient’s own stem cells has a significant positive effect on the heart’s recovery: in the patients studied, the size of the infarct was clearly reduced. The use of stem cells appears to be safe, and to date no side effects have occurred that can be attributed to the stem cells. This study is a world-first - its exciting results are being published in the prominent medical journal The Lancet.



In an acute myocardial infarction, the flow of blood from a blood vessel in the heart is blocked, whereby the cardiac muscle receives insufficient oxygen and heart tissue dies. In many cases, the supply of blood in the deadened portion of the heart can be restored via the so-called balloon technique. But the heart suffers permanent damage, primarily to the left ventricle.

The researchers in Leuven have tested the administration of bone marrow stem cells on patients stricken with acute myocardial infarction. In the 67 patients of the study, the supply of blood in the heart was restored optimally via the balloon technique. Then, within 24 hours, some patients received an injection of stem cells from their own bone marrow and some received an aqueous (placebo) solution (the patients in each group were selected by drawing lots). Such a double-blind, placebo-controlled study has never before been conducted.


Collaboration among the cardiology, hematology, radiology and nuclear medicine services yielded an unparalleled study in which state-of-the-art technology was used to investigate changes in the left ventricle, blood supply and heart metabolism.

Improvement in the global functioning of the left ventricle was comparable in both the control group (injected with the placebo) and the group that received the stem cells. But a clear global improvement in function was found in the sub-group of patients who had been afflicted with the most serious infarctions. Moreover, the reduction of the size of infarct was significantly greater in all patients in the ’stem cell group’ and correlates with a better preserved regional left ventricle function. It is still much too early to conclude that every patient with a myocardial infarction should be treated with stem cells. Indeed, there is still a long road to travel in the development of a medication, and no risks must be taken along the way.

One of the major scientific merits of this study is that it has investigated - in a rigorously controlled manner - the possible role as well as the limitations of the administration of stem cells. The findings are thus an important driving force for further targeted clinical and pre-clinical research. This study is the initial impetus for VIB and the Catholic University of Leuven and the newly established SCIL to quickly combine fundamental research on stem cells with clinical applications for the benefit of patients.

Ann Van Gysel | alfa
Further information:
http://www.vib.be

More articles from Life Sciences:

nachricht 'Y' a protein unicorn might matter in glaucoma
23.10.2017 | Georgia Institute of Technology

nachricht Microfluidics probe 'cholesterol' of the oil industry
23.10.2017 | Rice University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>